6-K/A 1 a4482vnew.htm HOLDING(S) IN COMPANY - REPLACEMENT a4482vnew
 
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of August 2022
 
Commission File Number: 001-41411
 
Haleon plc
(Translation of registrant’s name into English)
 
England and Wales
(Jurisdiction of Incorporation)
 
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address of principal executive offices)
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
 
 
Form 20-F ☒
 
Form 40-F ☐
 
 
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
 
 
 
 
 
 
 
EXHIBIT INDEX
 
Exhibit
Number
 
Description
99.1
 
Press Release entitled Holding(s) in Company – Replacement dated August 9, 2022
 
 
 
 
The following replaces the 'Holding(s) in Company' announcement released by Haleon plc (the "Company") on 4 August 2022.
 
This version corrects and replaces the notification made by Pfizer Inc. to the Company on 3 August 2022, as the Bank of America nominee entity is "BofA Securities, Inc.", instead of "N.Y. Nominees Limited".
 
The full amended text is shown below.
 
 
Haleon plc
 
 
TR-1: Standard form for notification of major holdings
 
1. Issuer Details
 
ISIN
GB00BMX86B70
 
Issuer Name
Haleon plc
 
UK or Non-UK Issuer
UK
 
 
 
2. Reason for Notification
 
Other
 
Comments
 
Change of nominee shareholder from Wealth Nominees Limited to BofA Securities, Inc.. See section 11 (additional information).
 
 
 
3. Details of person subject to the notification obligation
 
Name
Pfizer Inc.
 
City of registered office (if applicable)
New York
 
Country of registered office (if applicable)
United States of America
 
 
 
4. Details of the shareholder
 
Name
City of registered office
Country of registered office
Guaranty Nominees Limited
 
Bournemouth
 
United Kingdom
 
BofA Securities, Inc.
 
London
 
United Kingdom
 
5. Date on which the threshold was crossed or reached
 
03-Aug-2022
 
6. Date on which Issuer notified
 
03-Aug-2022
 
 
 
7. Total positions of person(s) subject to the notification obligation
 
 
% of voting rights attached to shares (total of 8.A)
% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B)
Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached
 
32.000000
 
0.000000
 
32.000000
 
2955063626
 
Position of previous notification (if applicable)
 
32.000000
 
0.000000
 
32.000000
 
 
 
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
 
8A. Voting rights attached to shares
 
Class/Type of shares ISIN code(if possible)
Number of direct voting rights (DTR5.1)
Number of indirect voting rights (DTR5.2.1)
% of direct voting rights (DTR5.1)
% of indirect voting rights (DTR5.2.1)
Ordinary Shares GB00BMX86B70
 
 
2364050902
 
 
25.600000
 
Restricted ADRs
 
 
591012724
 
 
6.400000
 
Sub Total 8.A
2955063626
 
32.000000%
 
 
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
 
Type of financial instrument
Expiration date
Exercise/conversion period
Number of voting rights that may be acquired if the instrument is exercised/converted
% of voting rights
 
 
 
 
 
 
Sub Total 8.B1
 
 
 
 
 
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
 
Type of financial instrument
Expiration date
Exercise/conversion period
Physical or cash settlement
Number of voting rights
% of voting rights
 
 
 
 
 
 
 
Sub Total 8.B2
 
 
 
 
 
9. Information in relation to the person subject to the notification obligation
 
1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.
 
 
 
Ultimate controlling person
Name of controlled undertaking
% of voting rights if it equals or is higher than the notifiable threshold
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold
Total of both if it equals or is higher than the notifiable threshold
 
 
 
 
 
 
 
10. In case of proxy voting
 
Name of the proxy holder
 
 
 
The number and % of voting rights held
 
 
 
The date until which the voting rights will be held
 
  
 
11. Additional Information
 
In relation to section 2 (reason for the notification), this notification is for information purposes only in relation to the transfer of Pfizer Inc. ("Pfizer")'s 2,364,050,902 ordinary shares in the capital of Haleon plc ("Haleon"), which were initially held by Wealth Nominees Limited as nominee holding on behalf of Pfizer, to BofA Securities, Inc. as nominee holding on behalf of Pfizer. This transfer completed on 3 August 2022.Since our last notification on 18 July 2022, there has been no change to the number of voting rights in Haleon held by Pfizer, and Pfizer has not crossed any shareholding thresholds.
 
This version corrects and replaces the notification made on 3 August 2022. The Bank of America nominee entity is "BofA Securities, Inc.", instead of "N.Y. Nominees Limited".
 
12. Date of Completion
 
08-Aug-2022
 
13. Place Of Completion
 
New York, USA
 
 
 
 
 
 
 
 
SIGNATURE
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
HALEON PLC
(Registrant)
 
Dated: August 9, 2022
By:
/s/ Amanda Mellor
 
 
Name:
Amanda Mellor
 
 
Title:
Company Secretary